{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Fennell DA"],"funding":["Cancer Research UK"],"pagination":["6688"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12280041"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive. Low non-synonymous mutation burden and programmed death-ligand 1 expression, an abundance of immunosuppressive immune cell infiltration, and 9p21 deletion should all mitigate responses to therapy. To address this knowledge gap, we conducted a double blind, placebo-controlled, randomized phase III trial of the PD1 inhibitor, nivolumab (ClinicalTrial.gov registration: NCT03063450). After 37.2 months of follow-up, the primary endpoint of progression free-survival, but not overall survival was met. The nivolumab response rate was 10.3%, and related grade 3 or above adverse events occurred in 20.4% versus 7.2%"],"journal":["Nature communications"],"pubmed_title":["Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial."],"pmcid":["PMC12280041"],"funding_grant_id":["C16728/A21400"],"pubmed_authors":["Darlison L","Johnson L","Nye M","Dzialo J","Califano R","Faulkner D","Jama M","Zhang M","Middleton C","Harber J","Poile C","Griffiths GO","Hollox EJ","Mallard K","Pritchard C","Hanna GG","Wells-Jordan P","Hill K","Zhou H","Chan S","Lester JF","Yang H","Nusrat N","Spicer J","Steele N","Klampatsa A","Luo JL","Ottensmeier C","Kamata T","Zhou Z","Baitei EY","Richards C","Ewings S","Hahne JC","Fennell DA","Rogel J","Bzura A","Danson S","Lord J","Szlosarek P"],"additional_accession":[]},"is_claimable":false,"name":"Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.","description":"Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive. Low non-synonymous mutation burden and programmed death-ligand 1 expression, an abundance of immunosuppressive immune cell infiltration, and 9p21 deletion should all mitigate responses to therapy. To address this knowledge gap, we conducted a double blind, placebo-controlled, randomized phase III trial of the PD1 inhibitor, nivolumab (ClinicalTrial.gov registration: NCT03063450). After 37.2 months of follow-up, the primary endpoint of progression free-survival, but not overall survival was met. The nivolumab response rate was 10.3%, and related grade 3 or above adverse events occurred in 20.4% versus 7.2%","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Jul","modification":"2026-07-15T10:55:03.152Z","creation":"2025-08-23T03:06:31.244Z"},"accession":"S-EPMC12280041","cross_references":{"pubmed":["40691143"],"doi":["10.1038/s41467-025-61691-4"]}}